Does Florida Blue (Blue Cross Blue Shield of Florida) Cover Forteo?

Florida Blue Formulary Placement for Forteo

Florida Blue places Forteo (teriparatide) on its specialty tier across commercial HMO, PPO, and POS plans. The drug appears on the Florida Blue Essential, Select, and Preferred formularies, though always subject to prior authorization and quantity limits.

Commercial Plan Coverage

On commercial plans, Forteo sits at Tier 4 (specialty) with a typical copay structure of 20 to 33% coinsurance after deductible. For a medication with a wholesale acquisition cost exceeding $4,000 per month, this translates to significant out-of-pocket expense without manufacturer assistance. Florida Blue's 2025 to 2026 formulary documents confirm Forteo's inclusion with "PA + ST" (prior authorization plus step therapy) designations [1].

Medicare Advantage Plans

Florida Blue Medicare Advantage (BlueMedicare) plans also cover Forteo under Part D specialty tiers. The Centers for Medicare & Medicaid Services requires Part D plans to cover at least two drugs in each therapeutic category. Forteo qualifies under the anabolic bone-forming agent category. BlueMedicare members face the Part D coverage gap (though the Inflation Reduction Act caps annual out-of-pocket at $2,000 starting 2025), which substantially reduces catastrophic-phase exposure for high-cost drugs like teriparatide [2].

Marketplace (ACA) Plans

Florida Blue ACA marketplace plans purchased through Healthcare.gov follow the same specialty formulary rules. These plans must comply with essential health benefit requirements, which include prescription drug coverage. Forteo remains accessible but subject to identical step therapy protocols.

Prior Authorization Requirements

Florida Blue will not approve Forteo without documentation that specific clinical criteria are met. The prior authorization process typically takes 5 to 10 business days for standard review or 24 to 72 hours for urgent/expedited requests.

Clinical Criteria for Approval

To receive authorization, your prescribing physician must document:

1. A confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) with a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip
2. Trial and failure of, or documented contraindication to, at least one oral bisphosphonate (alendronate or risedronate for a minimum of 12 months)
3. A history of fragility fracture OR T-score of -3.0 or worse with high fracture risk per FRAX calculation
4. Prescriber must be an endocrinologist, rheumatologist, or orthopedic specialist (primary care prescriptions may require additional documentation)

The Endocrine Society's 2020 clinical practice guideline supports anabolic therapy as first-line for patients at very high fracture risk, defined as recent fracture within 12 months, T-score below -3.0, or high FRAX probability [3]. Florida Blue's criteria align partially with this recommendation but still mandate bisphosphonate trial for most patients.

What Counts as Bisphosphonate Failure?

Florida Blue defines "failure" as:

• New fracture while on therapy for 12+ months
• Continued bone density loss (defined as ≥3% decline at any measured site) after 12 months of adherent use
• Documented intolerance (esophagitis, severe GI symptoms, osteonecrosis of the jaw, atypical femoral fracture)
• Contraindication (esophageal disorders, inability to remain upright 30 minutes, hypocalcemia, creatinine clearance <35 mL/min)

Submitting the Authorization

Physicians submit prior authorization through Florida Blue's Availity portal or by fax. Required documentation includes: recent DXA scan results (within 24 months), prescription history showing bisphosphonate use, lab work (calcium, vitamin D, renal function), and a letter of medical necessity. The American Association of Clinical Endocrinology recommends that clinicians document FRAX scores explicitly in authorization requests to strengthen approval likelihood [4].

Step Therapy Protocol

Florida Blue enforces a step therapy requirement that follows a predictable sequence. Understanding this sequence helps patients and physicians plan ahead.

Step 1: Oral Bisphosphonates

Alendronate (generic Fosamax) 70 mg weekly or risedronate (generic Actonel) 35 mg weekly for at least 12 months. Florida Blue requires claims history showing filled prescriptions, not just written prescriptions.

Step 2: Injectable Bisphosphonate or Denosumab

If oral bisphosphonates fail, some Florida Blue plans require a trial of zoledronic acid (Reclast) 5 mg IV annually or denosumab (Prolia) 60 mg subcutaneous every 6 months before approving Forteo. This second step is not universal across all Florida Blue plan designs but appears in approximately 30 to 40% of commercial policies.

Step 3: Forteo Approval

After documented failure of Step 1 (and Step 2 where applicable), Forteo receives authorization for up to 24 months. The FDA limits teriparatide use to 24 months based on the key Fracture Prevention Trial, which demonstrated a 65% reduction in new vertebral fractures and 53% reduction in non-vertebral fractures over a median 19-month treatment period [5].

Cost Breakdown With Florida Blue Coverage

The actual out-of-pocket cost varies significantly based on plan type, tier structure, deductible status, and whether manufacturer assistance is utilized.

Estimated Monthly Costs by Plan Type

For commercial PPO plans with 25% specialty coinsurance and a $3,000 specialty maximum: monthly cost runs approximately $250, $350 until the out-of-pocket maximum is reached. For HMO plans with fixed specialty copays: expect $75, $150 per fill. Medicare Advantage members face Part D tier pricing, but the $2,000 annual cap limits total exposure.

Manufacturer Savings Programs

Eli Lilly offers the Forteo Savings Card for commercially insured patients, reducing copays to as low as $4 per month for eligible individuals. This card does not apply to government insurance (Medicare, Medicaid, Tricare, VA). The Lilly Cares Foundation provides free medication for uninsured patients meeting income criteria [6].

Specialty Pharmacy Dispensing

Florida Blue requires Forteo to be dispensed through its designated specialty pharmacy network (Prime Specialty Pharmacy or Enhabit Rx). Patients cannot fill Forteo at retail pharmacies. The specialty pharmacy provides cold-chain shipping (teriparatide requires refrigeration at 2 to 8°C), injection training, and adherence monitoring.

What to Do If Florida Blue Denies Coverage

Denial rates for Forteo prior authorization run approximately 25 to 35% on initial submission, often due to incomplete documentation rather than true clinical ineligibility.

First-Level Appeal

Submit within 60 days of denial. Include: updated DXA results, detailed medication history with pharmacy claims, specialist letter explaining fracture risk, and FRAX printout. Reference the National Osteoporosis Foundation guidelines which support anabolic therapy for high-risk patients [7].

External Review

If internal appeals fail, Florida patients can request an external independent review through the Florida Office of Insurance Regulation. External reviewers are not bound by Florida Blue's internal formulary restrictions and evaluate medical necessity based on current clinical evidence.

Alternative Coverage Pathways

If Forteo remains inaccessible, consider:

• Abaloparatide (Tymlos), which may have different formulary placement on some Florida Blue plans
• Romosozumab (Evenity), another anabolic agent with distinct prior authorization criteria
• Denosumab (Prolia) as an antiresorptive alternative that may have lower tier placement

Clinical Context: Why Forteo Matters for Bone Health

Teriparatide is a recombinant parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than merely slowing bone loss. This anabolic mechanism distinguishes it from bisphosphonates and denosumab.

Fracture Reduction Evidence

The landmark Fracture Prevention Trial (N=1,637) demonstrated that teriparatide 20 mcg daily reduced new vertebral fractures by 65% and non-vertebral fractures by 53% compared to placebo over a median 19 months of treatment [5]. A 2020 meta-analysis published in the Journal of Bone and Mineral Research (N=5,902 across 23 trials) confirmed vertebral fracture risk reduction of 70% (RR 0.30, 95% CI 0.19 to 0.49) [8].

The VERO Trial

The VERO trial (N=1,360) directly compared teriparatide to risedronate in postmenopausal women with severe osteoporosis. At 24 months, teriparatide reduced new vertebral fractures by 56% compared to risedronate (HR 0.44, 95% CI 0.29 to 0.68, P<0.001) and clinical fractures by 52% [9]. This trial provides Level 1 evidence supporting teriparatide over bisphosphonates for patients at very high fracture risk.

Sequential Therapy Considerations

Dr. Felicia Cosman, writing in the Journal of Clinical Endocrinology & Metabolism, stated: "The treat-to-target approach in osteoporosis should begin with anabolic therapy in very high-risk patients, followed by antiresorptive consolidation, rather than reserving anabolics as last resort" [10].

Current evidence supports that starting with Forteo and transitioning to a bisphosphonate or denosumab preserves and extends bone density gains. The DATA-Switch study showed that women who received teriparatide followed by denosumab achieved the highest bone mineral density gains at the spine (+18.3%) and hip (+6.6%) over 4 years [11].

Florida-Specific Insurance Regulations Affecting Coverage

Florida state insurance law provides several protections relevant to Forteo access.

Step Therapy Override Rights

Florida Statute 627.42392 (effective 2020) grants patients the right to override step therapy requirements if:

• The required first-step medication is contraindicated
• The patient previously failed the required medication (even under a different insurer)
• The required medication is expected to cause harm based on clinical characteristics
• The patient is currently stable on Forteo from prior authorization

Continuity of Care Protections

If a Florida Blue member was previously authorized for Forteo and changes plans during open enrollment, Florida law requires the new plan to provide a temporary supply (typically 90 days) while new prior authorization is processed.

Network Adequacy

Florida requires insurers to maintain adequate specialty pharmacy access. If Florida Blue's designated specialty pharmacy cannot deliver Forteo within a reasonable timeframe, members can request an out-of-network exception at in-network cost.

Comparing Forteo Coverage Across Florida Insurers

Florida Blue's coverage policy for Forteo is moderately restrictive compared to other major Florida insurers.

Aetna Florida plans require similar step therapy but may accept a 6-month bisphosphonate trial rather than 12 months. UnitedHealthcare plans in Florida place Forteo on specialty tier with comparable coinsurance but sometimes waive the second step therapy requirement. Humana Medicare Advantage plans in Florida apply the standard Part D specialty tier with the $2,000 annual cap.

The key differentiator across insurers is not whether Forteo is covered (all major Florida carriers include it) but the stringency of prior authorization criteria and the number of step therapy hurdles required before approval.

Practical Steps to Get Forteo Covered by Florida Blue

A structured approach increases first-attempt approval rates.

Before Your Appointment

Request a DXA scan if your most recent scan is older than 24 months. Ask your pharmacy to print a medication history showing bisphosphonate fills and duration. Calculate your FRAX score at the University of Sheffield FRAX tool and bring the printout.

During Your Appointment

Ask your specialist to document: specific T-scores at each site, fracture history with dates and locations, bisphosphonate intolerance symptoms or treatment failure criteria, and explicit language stating "high fracture risk" or "very high fracture risk" per AACE/Endocrine Society definitions.

After Submission

Follow up with Florida Blue at 5 business days. If no decision has been made, request expedited review citing fracture risk. Keep your specialist's office informed so they can respond to any peer-to-peer review requests promptly. Peer-to-peer calls between your physician and Florida Blue's medical director often resolve borderline cases.